Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

When THC attaches to the receptor, the effect is like an off switch to a light bulb, effectively turning "off" the pain. But ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

In the Phase II MAIA lung cancer trial, THIO improved patients’ overall survival when taken in combination with Libtayo.

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

Study finds three new safe and effective drug regimens to fight multidrug-resistant TB. The treatments, which include recently discovered TB drugs, give new options for shorter, personalized treatment ...

Additionally, Libtayo sales of $289 million, while up 24% year-over-year, missed expectations. Regulatory setbacks, including the FDA’s complete response letter for linvoseltamab, further ...

As a doctor, I understand it is a critical issue and needs attention. To protect patients, even the World Health Organization has released guidelines on the quality of medical oxygen," Gopchade told ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Detailed results will be presented at an upcoming medical meeting and will be shared with regulatory ... research across diverse stages of skin cancer.” The potential use of Libtayo described above is ...